Bionoid Pharma Stock Probability of Future Pink Sheet Price Finishing Over 20.29
| BINP Stock | USD 0.23 0.02 8.00% |
Bionoid |
Bionoid Pharma Target Price Odds to finish over 20.29
The tendency of Bionoid Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 20.29 or more in 90 days |
| 0.23 | 90 days | 20.29 | close to zero percent |
Based on a normal probability distribution, the odds of Bionoid Pharma to move over $ 20.29 or more in 90 days from now is close to zero percent (This Bionoid Pharma probability density function shows the probability of Bionoid Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Bionoid Pharma price to stay between its current price of $ 0.23 and $ 20.29 at the end of the 90-day period is about 42.42 .
Given the investment horizon of 90 days Bionoid Pharma has a beta of 0.8 suggesting as returns on the market go up, Bionoid Pharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Bionoid Pharma will be expected to be much smaller as well. Moreover Bionoid Pharma has an alpha of 1.2993, implying that it can generate a 1.3 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Bionoid Pharma Price Density |
| Price |
Predictive Modules for Bionoid Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Bionoid Pharma. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Bionoid Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Bionoid Pharma is not an exception. The market had few large corrections towards the Bionoid Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Bionoid Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Bionoid Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.30 | |
β | Beta against Dow Jones | 0.80 | |
σ | Overall volatility | 0.05 | |
Ir | Information ratio | 0.07 |
Bionoid Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bionoid Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bionoid Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Bionoid Pharma is way too risky over 90 days horizon | |
| Bionoid Pharma has some characteristics of a very speculative penny stock | |
| Bionoid Pharma appears to be risky and price may revert if volatility continues | |
| Bionoid Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Bionoid Pharma currently holds 64.5 K in liabilities. Bionoid Pharma has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Bionoid Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Bionoid Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bionoid Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bionoid to invest in growth at high rates of return. When we think about Bionoid Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 92.26 K. Net Loss for the year was (1.62 M) with profit before overhead, payroll, taxes, and interest of 47.48 K. | |
| Bionoid Pharma currently holds about 127 in cash with (357.62 K) of positive cash flow from operations. |
Bionoid Pharma Technical Analysis
Bionoid Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. Bionoid Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Bionoid Pharma. In general, you should focus on analyzing Bionoid Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Bionoid Pharma Predictive Forecast Models
Bionoid Pharma's time-series forecasting models is one of many Bionoid Pharma's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Bionoid Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Bionoid Pharma
Checking the ongoing alerts about Bionoid Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Bionoid Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Bionoid Pharma is way too risky over 90 days horizon | |
| Bionoid Pharma has some characteristics of a very speculative penny stock | |
| Bionoid Pharma appears to be risky and price may revert if volatility continues | |
| Bionoid Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Bionoid Pharma currently holds 64.5 K in liabilities. Bionoid Pharma has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Bionoid Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Bionoid Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bionoid Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bionoid to invest in growth at high rates of return. When we think about Bionoid Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 92.26 K. Net Loss for the year was (1.62 M) with profit before overhead, payroll, taxes, and interest of 47.48 K. | |
| Bionoid Pharma currently holds about 127 in cash with (357.62 K) of positive cash flow from operations. |
Additional Tools for Bionoid Pink Sheet Analysis
When running Bionoid Pharma's price analysis, check to measure Bionoid Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionoid Pharma is operating at the current time. Most of Bionoid Pharma's value examination focuses on studying past and present price action to predict the probability of Bionoid Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionoid Pharma's price. Additionally, you may evaluate how the addition of Bionoid Pharma to your portfolios can decrease your overall portfolio volatility.